Astellas Pharma Inc. and Medivation, Inc. Release: MDV3100 Extends Life by Nearly Five Months in Men with Advanced Prostate Cancer Post Chemotherapy 1

Published: Feb 27, 2012

STAINES, England--(BUSINESS WIRE)--Astellas Pharma Europe Ltd. (APEL) announced today that data presented at the European Association of Urology (EAU) congress in Paris, France, have shown that the investigational drug MDV3100 extended life by nearly 5 months, compared to placebo, in men with advanced prostate cancer, previously treated with chemotherapy.

Back to news